Indomethacin responsiveness of patent ductus arteriosus and renal abnormalities in preterm infants treated with indomethacin
- PMID: 12970633
- DOI: 10.1067/S0022-3476(03)00303-2
Indomethacin responsiveness of patent ductus arteriosus and renal abnormalities in preterm infants treated with indomethacin
Abstract
Objectives: We evaluated the factors related to indomethacin responsiveness of the patent ductus arteriosus (PDA) and subsequent renal and electrolyte abnormalities in a large number of low birth weight infants.
Methods: The ductus was evaluated by Doppler echocardiogram or clinical signs after the last administration of indomethacin for 2538 low birth weight infants, through the use of postmarketing surveillance data.
Results: Multivariate logistic regression analyses demonstrated that clinical closure of PDA was significantly associated with pregnancy-induced hypertension and respiratory distress syndrome. In contrast, a 1-point increase of cardiovascular dysfunction score or a 1-day increase in postnatal age at the first indomethacin treatment decreased the responsiveness of the ductus to indomethacin. Clinical ductal reopening was significantly less likely to occur for each week of increased gestational age. Ductal reopening was more likely for each day of postnatal life at the first administration of indomethacin. Infants with preexisting renal and electrolyte abnormalities and infants whose mothers had received indomethacin tocolysis or who had chorioamnionitis were at increased risk of development of renal impairment.
Conclusions: Both antenatal and postnatal factors predict good or poor response to indomethacin therapy for PDA.
Similar articles
-
Predictors of ductal closure and intestinal complications in very low birth weight infants treated with indomethacin.Neonatology. 2008;94(1):45-51. doi: 10.1159/000113058. Epub 2008 Jan 15. Neonatology. 2008. PMID: 18196930
-
The effects of indomethacin tocolysis on the postnatal response of the ductus arteriosus to indomethacin in extremely low birth weight infants.J Perinatol. 2007 Jan;27(1):22-7. doi: 10.1038/sj.jp.7211612. Epub 2006 Oct 19. J Perinatol. 2007. PMID: 17053778
-
A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus.N Engl J Med. 2000 Sep 7;343(10):674-81. doi: 10.1056/NEJM200009073431001. N Engl J Med. 2000. PMID: 10974130 Clinical Trial.
-
Pharmacologic management of patent ductus arteriosus.Clin Pharm. 1989 Jan;8(1):17-33. Clin Pharm. 1989. PMID: 2643499 Review.
-
Ibuprofen lysine for the prevention and treatment of patent ductus arteriosus.Pharmacotherapy. 2008 Sep;28(9):1162-82. doi: 10.1592/phco.28.9.1162. Pharmacotherapy. 2008. PMID: 18752387 Review.
Cited by
-
Factors Predicting Spontaneous Closure of Patent Ductus Arteriosus in Very Low Birth Weight Neonates.Cureus. 2024 Aug 30;16(8):e68241. doi: 10.7759/cureus.68241. eCollection 2024 Aug. Cureus. 2024. PMID: 39347222 Free PMC article.
-
Plasma B-type natriuretic peptide cannot predict treatment response to ibuprofen in preterm infants with patent ductus arteriosus.Sci Rep. 2020 Mar 10;10(1):4430. doi: 10.1038/s41598-020-61291-w. Sci Rep. 2020. PMID: 32157119 Free PMC article.
-
Outcomes of small for gestational age micropremies depending on how young or how small they are.Korean J Pediatr. 2011 Jun;54(6):246-52. doi: 10.3345/kjp.2011.54.6.246. Epub 2011 Jun 30. Korean J Pediatr. 2011. PMID: 21949519 Free PMC article.
-
Efficacy of pharmacologic closure of patent ductus arteriosus in small-for-gestational-age extremely preterm infants.Early Hum Dev. 2017 Oct;113:10-17. doi: 10.1016/j.earlhumdev.2017.07.011. Epub 2017 Jul 8. Early Hum Dev. 2017. PMID: 28697406 Free PMC article. Clinical Trial.
-
Multiple courses of indomethacin and neonatal outcomes in premature infants.Pediatr Cardiol. 2008 Sep;29(5):878-84. doi: 10.1007/s00246-007-9166-z. Epub 2007 Dec 18. Pediatr Cardiol. 2008. PMID: 18094917 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical